Global intravenous immunoglobulin market is expected to
reach USD 10.9 billion by 2022, according to a new study by Grand View
Research, Inc.
The increasing prevalence of immunodeficiency
diseases coupled with the adoption of IVIG therapies is expected to fuel market
growth over the forecast period. In addition, increasing off-label use of
immunoglobulin and investments in the healthcare sector are factors propelling
market growth. Moreover, increasing incidences of bleeding disorders and rising
geriatric population base are the factors attributing towards the industry
growth.
The rising incorporation of subcutaneous
immunoglobulin in the treatment of primary immunodeficiency diseases and in
replacement therapy is anticipated to provide growth platform to the
immunoglobulin market in the next seven years.
Browse full research report on Intravenous
Immunoglobulin (IVIG) Market:
https://www.grandviewresearch.com/industry-analysis/intravenous-immunoglobulin-market
Further key
findings from the study suggest:
- Increasing demand for immunoglobulin
replacement therapies to treat hypogammaglobulinemia diseases is driven by
rising awareness levels amongst patients and increasing incidences of the
disease. This has attributed towards hypogammaglobulinemia diseases
segment’s dominant market share in 2014
- The U.S. National library of Medicine and the
National Institute of Health published a report, which states that in
2012, about 6 million patients suffered from PID (Primary immunodeficiency
Diseases) globally and is expected to grow further, representing the
potential growth for the treatment of hypogammaglobulinemia in the coming
years
- The Kawasaki disease market segment is
expected to grow at a rapid pace with a lucrative CAGR of over 8.0% from
2015 to 2022 owing to the massive adoption of IVIG treatment in the
aforementioned disease management
- Intravenous route of administration is most
commonly used in the treatment of autoimmune diseases and accounted for
the largest market share in 2014. Subcutaneous administration is
anticipated to be growing at a lucrative CAGR of over 9.0% during the
forecast period. This can be attributed to the associated potential
advantages such as fewer side effects and shorter response time with
subcutaneous route of administration and rising preference for
subcutaneous home-based self-infusion
- North America held the largest regional market
share in terms of revenue in 2014 due to the presence of a well-regulated
healthcare system, the larger pool of target population, and high patient
awareness pertinent to the plasma protein products
- The European intravenous immunoglobulin market
is expected to show an impressive CAGR at above 6.0% over the forecast
period owing to the increasing number of patients with bleeding disorders
and growing number of CIDP patients
- Countries such as India, China, and South
Africa are expected to show significant growth over the forecast period
owing to improving healthcare facilities, rising healthcare expenditure,
and growing public awareness of immune deficiency disorders
- Chinese IVIG market is poised to show a growth
rate of over 7.0% owing to the presence of major market players such as
China Biologics Products, Inc. facilitating the industry growth
- Some key players of IVIG industry are Biotest
AG, Octapharma AG, China Biologics Products Ltd., Baxter international,
Inc., CSL Limited, LFB group and Grifols S.A.
- These key players are adopting strategic
alliances to sustain the competition. These initiatives include mergers
& acquisitions, collaborations, and new product developments.
- For instance, in January 2016, Biotest AG
entered into a collaborative agreement with Kedrion Pharma to expand the
distribution capabilities of Bivigam. This was carried out to improve
production facility utilization and manage idle capacity costs enabling
better optimization.
Browse request sample of this report by
Grand View Research: https://www.grandviewresearch.com/industry-analysis/intravenous-immunoglobulin-market/request/rs1
Grand
View Research has segmented the global intravenous immunoglobulin market on the
basis of application and region:
Global
Intravenous Immunoglobulin Market Application Outlook (Revenue, USD
Million, 2012 - 2022)
- Hypogammaglobulinemia
- CIPD
- Immunodeficiency
diseases
- Congenital AIDS
- Chronic Lymphocytic
Leukemia
- Myasthenia Gravis
- Multifocal motor
neuropathy
- ITP
- Kawasaki disease
- Guillain-Barre
syndrome
- Others
Global
Immunoglobulin Market Route of Administration Outlook (Revenue, USD
Million, 2012 - 2022)
- Intravenous
- Subcutaneous
Intravenous
Immunoglobulin Regional Outlook (Revenue, USD Million, 2012 - 2022)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia Pacific
- Japan
- China
- India
- Latin America
- Mexico
- Brazil
- MEA
- South Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment